@article{JTD9062,
author = {Zu-Yang Yuan and Shu-Geng Gao and Ju-Wei Mu and Qi Xue and You-Sheng Mao and Da-Li Wang and Jun Zhao and Yu-Shun Gao and Jin-Feng Huang and Jie He},
title = {Prognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {9},
year = {2016},
keywords = {},
abstract = {Background: The prognostic value of serum lactate dehydrogenase (LDH) has been demonstrated in various solid tumors. We attempted to determine whether serum LDH was predictive of survival in thymic carcinoma after surgical resection.
Methods: Ninety-five patients with thymic carcinoma treated in our hospital between January 2005 and December 2015 were retrospectively enrolled. Serum LDH was measured before surgery and categorized as low or high relative to the upper limit of normal (ULN) (225 U/L). The relationships of serum LDH level and other clinical variables with survival were estimated by Cox regression and Kaplan-Meier survival analysis.
Results: Serum LDH levels were found to be significantly associated with overall survival (OS) and progression-free survival (PFS) of these patients. The 1-, 3-, and 5-year PFS were 76%, 51%, and 38%, and the 1-, 3- and 5-year OS were 97%, 75%, and 46%, respectively. Univariate analysis found that high serum LDH (>225 U/L) was associated with both lower OS [hazard ratio (HR) =2.710; 95% confidence interval (CI): 1.363–1.5.391; P=0.004] and PFS (HR =3.365; 95% CI: 1.776–6.374; P225 U/L) was an independent predictor of decreased PFS in thymic carcinoma patients. It was also significantly associated with reduced OS, but was not an independent predictor of death in those patients.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/9062}
}